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Overview {#bph14750-sec-0003}
--------

Nuclear receptors are specialised transcription factors with commonalities of sequence and structure, which bind as homo‐ or heterodimers to specific consensus sequences of DNA (response elements) in the promoter region of particular target genes. They regulate (either promoting or repressing) transcription of these target genes in response to a variety of endogenous ligands. Endogenous agonists are hydrophobic entities which, when bound to the receptor promote conformational changes in the receptor to allow recruitment (or dissociation) of protein partners, generating a large multiprotein complex.

Two major subclasses of nuclear receptors with identified endogenous agonists can be identified: steroid and non‐steroid hormone receptors. Steroid hormone receptors function typically as dimeric entities and are thought to be resident outside the nucleus in the unliganded state in a complex with chaperone proteins, which are liberated upon agonist binding. Migration to the nucleus and interaction with other regulators of gene transcription, including RNA polymerase, acetyltransferases and deacetylases, allows gene transcription to be regulated. Non‐steroid hormone receptors typically exhibit a greater distribution in the nucleus in the unliganded state and interact with other nuclear receptors to form heterodimers, as well as with other regulators of gene transcription, leading to changes in gene transcription upon agonist binding.

Selectivity of gene regulation is brought about through interaction of nuclear receptors with particular consensus sequences of DNA, which are arranged typically as repeats or inverted palindromes to allow accumulation of multiple transcription factors in the promoter regions of genes.

Family structure {#bph14750-sec-0004}
----------------

[S230 1A. Thyroid hormone receptors](#bph14750-sec-0005){ref-type="sec"}

[S231 1B. Retinoic acid receptors](#bph14750-sec-0009){ref-type="sec"}

[S232 1C. Peroxisome proliferator‐activated receptors](#bph14750-sec-0013){ref-type="sec"}

[S233 1D. Rev‐Erb receptors](#bph14750-sec-0017){ref-type="sec"}

[S234 1F. Retinoic acid‐related orphans](#bph14750-sec-0020){ref-type="sec"}

[S234 1H. Liver X receptor‐like receptors](#bph14750-sec-0024){ref-type="sec"}

[S235 1I. Vitamin D receptor‐like receptors](#bph14750-sec-0028){ref-type="sec"}

[S236 2A. Hepatocyte nuclear factor‐4 receptors](#bph14750-sec-0031){ref-type="sec"}

[S237 2B. Retinoid X receptors](#bph14750-sec-0034){ref-type="sec"}

[S238 2C. Testicular receptors](#bph14750-sec-0037){ref-type="sec"}

[S238 2E. Tailless‐like receptors](#bph14750-sec-0040){ref-type="sec"}

[S239 2F. COUP‐TF‐like receptors](#bph14750-sec-0043){ref-type="sec"}

[S239 3B. Estrogen‐related receptors](#bph14750-sec-0046){ref-type="sec"}

[S240 4A. Nerve growth factor IB‐like receptors](#bph14750-sec-0049){ref-type="sec"}

[S241 5A. Fushi tarazu F1‐like receptors](#bph14750-sec-0052){ref-type="sec"}

[S241 6A. Germ cell nuclear factor receptors](#bph14750-sec-0055){ref-type="sec"}

[S242 0B. DAX‐like receptors](#bph14750-sec-0058){ref-type="sec"}

[S242 Steroid hormone receptors](#bph14750-sec-0061){ref-type="sec"}

[S243 3A. Estrogen receptors](#bph14750-sec-0063){ref-type="sec"}

[S244 3C. 3‐Ketosteroid receptors](#bph14750-sec-0067){ref-type="sec"}

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=84> {#bph14750-sec-0005}
==========================================================================

Overview {#bph14750-sec-0006}
--------

Thyroid hormone receptors (**TRs, nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132849?dopt=AbstractPlus> **\]**) are nuclear hormone receptors of the NR1A family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635>) and thyroid hormone (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634>). Once activated by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2633> has been described as an antagonist at TRs with modest selectivity for TRβ \[<http://www.ncbi.nlm.nih.gov/pubmed/12109914?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=588><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=589>Systematic nomenclatureNR1A1NR1A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11796](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11796), <http://www.uniprot.org/uniprot/P10827>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11799](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11799), <http://www.uniprot.org/uniprot/P10828>Rank order of potency<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6951> \[<http://www.ncbi.nlm.nih.gov/pubmed/6777394?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6951> \[<http://www.ncbi.nlm.nih.gov/pubmed/6777394?dopt=AbstractPlus>\]Selective agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2639> \[<http://www.ncbi.nlm.nih.gov/pubmed/9653548?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/269396?dopt=AbstractPlus>\]

Comments {#bph14750-sec-0007}
--------

An interaction with integrin αVβ3 has been suggested to underlie plasma membrane localization of TRs and non‐genomic signalling \[<http://www.ncbi.nlm.nih.gov/pubmed/15802494?dopt=AbstractPlus>\].One splice variant, TRα~2~, lacks a functional DNA‐binding domain and appears to act as a transcription suppressor.

Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.

Further reading on 1A. Thyroid hormone receptors {#bph14750-sec-0008}
------------------------------------------------

Elbers LP *et al*. (2016) Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges. *Curr Atheroscler Rep* **18**: 14 <https://www.ncbi.nlm.nih.gov/pubmed/26886134?dopt=AbstractPlus>

Flamant F *et al*. (2006) International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. *Pharmacol. Rev*. **58**: 705‐11 <https://www.ncbi.nlm.nih.gov/pubmed/17132849?dopt=AbstractPlus>

Mendoza A *et al*. (2017) New insights into thyroid hormone action. *Pharmacol. Ther*. **173**: 135‐145 <https://www.ncbi.nlm.nih.gov/pubmed/28174093?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=85> {#bph14750-sec-0009}
==========================================================================

Overview {#bph14750-sec-0010}
--------

Retinoic acid receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132850?dopt=AbstractPlus> **\]**) are nuclear hormone receptors of the NR1B family activated by the vitamin A‐derived agonists <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644> (ATRA) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645>, and the RAR‐selective synthetic agonists <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2646> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429>. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2641> is a family‐selective antagonist \[<http://www.ncbi.nlm.nih.gov/pubmed/19477412?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=590><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=591><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=592>Systematic nomenclatureNR1B1NR1B2NR1B3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9864](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9864), <http://www.uniprot.org/uniprot/P10276>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9865](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9865), <http://www.uniprot.org/uniprot/P10826>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9866](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9866), <http://www.uniprot.org/uniprot/P13631>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644> \[<http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644> \[<http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644> \[<http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus>\]Sub/family‐selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952> \[<http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952> \[<http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429> \[<http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952> \[<http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429> \[<http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus>\]Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2650> \[<http://www.ncbi.nlm.nih.gov/pubmed/10421757?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2648> \[<http://www.ncbi.nlm.nih.gov/pubmed/20925433?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2647> \[<http://www.ncbi.nlm.nih.gov/pubmed/1656191?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4054> \[<http://www.ncbi.nlm.nih.gov/pubmed/16302793?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4055> \[<http://www.ncbi.nlm.nih.gov/pubmed/19239230?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16302793?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3431> \[<http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2642> (pIC~50~ 6.3--7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/1323127?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8264595?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4062> \[<http://www.ncbi.nlm.nih.gov/pubmed/10723137?dopt=AbstractPlus>\]

Comments {#bph14750-sec-0011}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2642> has been suggested to be a PPARγ agonist \[<http://www.ncbi.nlm.nih.gov/pubmed/17290005?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3433> is an antagonist with selectivity for RARα and RARβ compared with RARγ \[<http://www.ncbi.nlm.nih.gov/pubmed/10331664?dopt=AbstractPlus>\].

Further reading on 1B. Retinoic acid receptors {#bph14750-sec-0012}
----------------------------------------------

Duong V *et al*. (2011) The molecular physiology of nuclear retinoic acid receptors. From health to disease. *Biochim. Biophys. Acta* **1812**: 1023‐31 \[<https://www.ncbi.nlm.nih.gov/pubmed/20970498?dopt=AbstractPlus>\]

Germain P *et al*. (2006) International Union of Pharmacology. LX. Retinoic acid receptors. *Pharmacol. Rev*. **58**: 712‐25 <https://www.ncbi.nlm.nih.gov/pubmed/17132850?dopt=AbstractPlus>

Larange A *et al*. (2016) Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the Immune System. *Annu. Rev. Immunol*. **34**: 369‐94 <https://www.ncbi.nlm.nih.gov/pubmed/27168242?dopt=AbstractPlus>

Saeed A *et al*. (2017) The interrelationship between bile acid and vitamin A homeostasis. *Biochim. Biophys. Acta* **1862**: 496‐512 <https://www.ncbi.nlm.nih.gov/pubmed/28111285?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=86> {#bph14750-sec-0013}
==========================================================================

Overview {#bph14750-sec-0014}
--------

Peroxisome proliferator‐activated receptors (**PPARs, nomenclature as agreed by the** [NC‐IUPHAR]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[<http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus>\]) are nuclear hormone receptors of the NR1C family, with diverse roles regulating lipid homeostasis, cellular differentiation, proliferation and the immune response. PPARs have many potential endogenous agonists \[<http://www.ncbi.nlm.nih.gov/pubmed/12749590?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus>\], including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1877>, prostacyclin (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915>), many fatty acids and their oxidation products, lysophosphatidic acid (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906>) \[<http://www.ncbi.nlm.nih.gov/pubmed/12502787?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5426>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5427>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5428> and leukotriene B4 (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487>). <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2668> acts as a non‐selective agonist for the PPAR family \[<http://www.ncbi.nlm.nih.gov/pubmed/10691680?dopt=AbstractPlus>\]. These receptors also bind hypolipidaemic drugs (PPARα) and anti‐diabetic thiazolidinediones (PPARγ), as well as many non‐steroidal anti‐inflammatory drugs, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5425> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909>. Once activated by a ligand, the receptor forms a heterodimer with members of the retinoid X receptor family and can act as a transcription factor. Although radioligand binding assays have been described for all three receptors, the radioligands are not commercially available. Commonly, receptor occupancy studies are conducted using fluorescent ligands and truncated forms of the receptor limited to the ligand binding domain.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=594><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=595>Systematic nomenclatureNR1C1NR1C2NR1C3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9232](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9232), <http://www.uniprot.org/uniprot/Q07869>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9235](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9235), <http://www.uniprot.org/uniprot/Q03181>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9236](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9236), <http://www.uniprot.org/uniprot/P37231>Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2674> \[<http://www.ncbi.nlm.nih.gov/pubmed/10389847?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11354382?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6691> \[<http://www.ncbi.nlm.nih.gov/pubmed/18971326?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2666> \[<http://www.ncbi.nlm.nih.gov/pubmed/10691680?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439> \[<http://www.ncbi.nlm.nih.gov/pubmed/21889235?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2686> \[<http://www.ncbi.nlm.nih.gov/pubmed/15939051?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12699745?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2687> \[<http://www.ncbi.nlm.nih.gov/pubmed/11309497?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2703> \[<http://www.ncbi.nlm.nih.gov/pubmed/10389847?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2717> (Partial agonist) \[<http://www.ncbi.nlm.nih.gov/pubmed/11043571?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056> \[<http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9013583?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2693> \[<http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2694> \[<http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11095972?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2711> \[<http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3440> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11845213?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3441> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17975020?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3444> (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/11877444?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3442> (Irreversible inhibition) (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/12022867?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3443> (p*K* ~i~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/11043571?dopt=AbstractPlus>\]

Comments {#bph14750-sec-0015}
--------

As with the estrogen receptor antagonists, many agents show tissue‐selective efficacy (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/11030710?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11991651?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11684010?dopt=AbstractPlus>\]). Agonists with mixed activity at PPARα and PPARγ have also been described (*e.g* \[<http://www.ncbi.nlm.nih.gov/pubmed/15120604?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14701675?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15115385?dopt=AbstractPlus>\]).

Further reading on 1C. Peroxisome proliferator‐activated receptors {#bph14750-sec-0016}
------------------------------------------------------------------

Cheang WS *et al*. (2015) The peroxisome proliferator‐activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. *Br. J. Pharmacol*. **172**: 5512‐22 \[<https://www.ncbi.nlm.nih.gov/pubmed/25438608?dopt=AbstractPlus>\]

Gross B *et al*. (2017) PPARs in obesity‐induced T2DM, dyslipidaemia and NAFLD. *Nat Rev Endocrinol* **13**: 36‐49 \[<https://www.ncbi.nlm.nih.gov/pubmed/27636730?dopt=AbstractPlus>\]

Hallenborg P *et al*. (2016) The elusive endogenous adipogenic PPARγ agonists: Lining up the suspects. *Prog. Lipid Res*. **61**: 149‐62 \[<https://www.ncbi.nlm.nih.gov/pubmed/26703188?dopt=AbstractPlus>\]

Michalik L *et al*. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator‐activated receptors. *Pharmacol. Rev*. **58**: 726‐41 \[<https://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus>\]

Sauer S. (2015) Ligands for the Nuclear Peroxisome Proliferator‐Activated Receptor Gamma. *Trends Pharmacol. Sci*. **36**: 688‐704 \[<https://www.ncbi.nlm.nih.gov/pubmed/26435213?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=87> {#bph14750-sec-0017}
==========================================================================

Overview {#bph14750-sec-0018}
--------

Rev‐erb receptors (**nomenclature as agreed by the** [NC‐IUPHAR]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[<http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>\]) have yet to be officially paired with an endogenous ligand, but are thought to be activated by heme.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=596><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=597>Systematic nomenclatureNR1D1NR1D2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7962](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7962), <http://www.uniprot.org/uniprot/P20393>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7963](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7963), <http://www.uniprot.org/uniprot/Q14995>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349> \[<http://www.ncbi.nlm.nih.gov/pubmed/18037887?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18006707?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349> \[<http://www.ncbi.nlm.nih.gov/pubmed/24872411?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18037887?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18006707?dopt=AbstractPlus>\]Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2903> \[<http://www.ncbi.nlm.nih.gov/pubmed/20677822?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2903> \[<http://www.ncbi.nlm.nih.gov/pubmed/21043485?dopt=AbstractPlus>\]--Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2904> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21043485?dopt=AbstractPlus>\]--

Further reading on 1D. Rev‐Erb receptors {#bph14750-sec-0019}
----------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 \[<https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>\]

Gonzalez‐Sanchez E *et al*. (2015) Nuclear receptors in acute and chronic cholestasis. *Dig Dis* **33**: 357‐66 \[<https://www.ncbi.nlm.nih.gov/pubmed/26045270?dopt=AbstractPlus>\]

Gustafson CL *et al*. (2015) Emerging models for the molecular basis of mammalian circadian timing. *Biochemistry* **54**: 134‐49 \[<https://www.ncbi.nlm.nih.gov/pubmed/25303119?dopt=AbstractPlus>\]

Sousa EH *et al*. (2017) Drug discovery targeting heme‐based sensors and their coupled activities. *J. Inorg. Biochem*. **167**: 12‐20 \[<https://www.ncbi.nlm.nih.gov/pubmed/27893989?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=88> {#bph14750-sec-0020}
==========================================================================

Overview {#bph14750-sec-0021}
--------

Retinoic acid receptor‐related orphan receptors (ROR, **nomenclature as agreed by the** [NC‐IUPHAR]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[<http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>\]) have yet to be assigned a definitive endogenous ligand, although RORα may be synthesized with a 'captured' agonist such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718> \[<http://www.ncbi.nlm.nih.gov/pubmed/14722075?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=598><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=599><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=600>Systematic nomenclatureNR1F1NR1F2NR1F3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10258](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10258), <http://www.uniprot.org/uniprot/P35398>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10259](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10259), <http://www.uniprot.org/uniprot/Q92753>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10260](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10260), <http://www.uniprot.org/uniprot/P51449>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718> \[<http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8858107?dopt=AbstractPlus>\]----Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3432> \[<http://www.ncbi.nlm.nih.gov/pubmed/14622968?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2738> \[<http://www.ncbi.nlm.nih.gov/pubmed/14622968?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus>\]----Comments----The immune system function of RORC proteins most likely resides with expression of the RORγt isoform by immature CD4^+^/CD8^+^ cells in the thymus \[<http://www.ncbi.nlm.nih.gov/pubmed/15247480?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10875923?dopt=AbstractPlus>\] and in lymphoid tissue inducer (LTi) cells \[<http://www.ncbi.nlm.nih.gov/pubmed/14691482?dopt=AbstractPlus>\].

Comments {#bph14750-sec-0022}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644> shows selectivity for RORβ within the ROR family \[<http://www.ncbi.nlm.nih.gov/pubmed/12958591?dopt=AbstractPlus>\]. RORα has been suggested to be a nuclear receptor responding to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224> \[<http://www.ncbi.nlm.nih.gov/pubmed/7885826?dopt=AbstractPlus>\].

Further reading on 1F. Retinoic acid‐related orphans {#bph14750-sec-0023}
----------------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 \[<https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>\]

Cyr P *et al*. (2016) Recent progress on nuclear receptor RORγ modulators. *Bioorg. Med. Chem. Lett*. **26**: 4387‐4393 \[<https://www.ncbi.nlm.nih.gov/pubmed/27542308?dopt=AbstractPlus>\]

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 \[<https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>\]

Guillemot‐Legris O *et al*. (2016) Oxysterols in Metabolic Syndrome: From Bystander Molecules to Bioactive Lipids. *Trends Mol Med* **22**: 594‐614 \[<https://www.ncbi.nlm.nih.gov/pubmed/27286741?dopt=AbstractPlus>\]

Mutemberezi V *et al*. (2016) Oxysterols: From cholesterol metabolites to key mediators. *Prog. Lipid Res*. **64**: 152‐169 \[<https://www.ncbi.nlm.nih.gov/pubmed/27687912?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=89> {#bph14750-sec-0024}
==========================================================================

Overview {#bph14750-sec-0025}
--------

Liver X and farnesoid X receptors (LXR and FXR, **nomenclature as agreed by the** [NC‐IUPHAR]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[<http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus>\]) are members of a steroid analogue‐activated nuclear receptor subfamily, which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs appear to be activated by bile acids. In humans and primates, *NR1H5P* is a pseudogene. However, in other mammals, it encodes a functional nuclear hormone receptor that appears to be involved in cholesterol biosynthesis \[<http://www.ncbi.nlm.nih.gov/pubmed/12529392?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=603><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=604><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=602><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=601>Systematic nomenclatureNR1H4NR1H5NR1H3NR1H2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7967](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7967), <http://www.uniprot.org/uniprot/Q96RI1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:32673](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:32673), --[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7966](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7966), <http://www.uniprot.org/uniprot/Q13133>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7965](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7965), <http://www.uniprot.org/uniprot/P55055>Potency order<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=608> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=610> \[<http://www.ncbi.nlm.nih.gov/pubmed/10334992?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10334993?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3434>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2742>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2885>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752> \[<http://www.ncbi.nlm.nih.gov/pubmed/9013544?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3434>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2742>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2885>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752> \[<http://www.ncbi.nlm.nih.gov/pubmed/9013544?dopt=AbstractPlus>\]Endogenous agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746> \[<http://www.ncbi.nlm.nih.gov/pubmed/12529392?dopt=AbstractPlus>\] -- Mouse----Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2743> \[<http://www.ncbi.nlm.nih.gov/pubmed/10956205?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3435> \[<http://www.ncbi.nlm.nih.gov/pubmed/12166927?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2744> \[<http://www.ncbi.nlm.nih.gov/pubmed/12718892?dopt=AbstractPlus>\]------Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2745> (pIC~50~ 5.7--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/12089353?dopt=AbstractPlus>\]------

Comments {#bph14750-sec-0026}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2755> \[<http://www.ncbi.nlm.nih.gov/pubmed/10968783?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2754> \[<http://www.ncbi.nlm.nih.gov/pubmed/11985463?dopt=AbstractPlus>\] are synthetic agonists acting at both LXRα and LXRβ with less than 10‐fold selectivity.

Further reading on 1H. Liver X receptor‐like receptors {#bph14750-sec-0027}
------------------------------------------------------

Courtney R *et al*. (2016) LXR Regulation of Brain Cholesterol: From Development to Disease. *Trends Endocrinol. Metab*. **27**: 404‐414 \[<https://www.ncbi.nlm.nih.gov/pubmed/27113081?dopt=AbstractPlus>\]

El‐Gendy BEM *et al*. (2018) Recent Advances in the Medicinal Chemistry of Liver X Receptors. *J. Med. Chem*. **61**: 10935‐10956 \[<https://www.ncbi.nlm.nih.gov/pubmed/30004226?dopt=AbstractPlus>\]

Gadaleta RM *et al*. (2010) Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. *Biochim. Biophys. Acta* **1801**: 683‐92 \[<https://www.ncbi.nlm.nih.gov/pubmed/20399894?dopt=AbstractPlus>\]

Merlen G *et al*. (2017) Bile acids and their receptors during liver regeneration: "Dangerous protectors". *Mol. Aspects Med*. **56**: 25‐33 \[<https://www.ncbi.nlm.nih.gov/pubmed/28302491?dopt=AbstractPlus>\]

Moore DD *et al*. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. *Pharmacol. Rev*. **58**: 742‐59 \[<https://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus>\]

Mouzat K *et al*. (2016) Liver X receptors: from cholesterol regulation to neuroprotection‐a new barrier against neurodegeneration in amyotrophic lateral sclerosis? *Cell. Mol. Life Sci*. **73**: 3801‐8 \[<https://www.ncbi.nlm.nih.gov/pubmed/27510420?dopt=AbstractPlus>\]

Schulman IG. (2017) Liver X receptors link lipid metabolism and inflammation. *FEBS Lett*. **591**: 2978‐2991 \[<https://www.ncbi.nlm.nih.gov/pubmed/28555747?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=90> {#bph14750-sec-0028}
==========================================================================

Overview {#bph14750-sec-0029}
--------

Vitamin D (VDR), Pregnane X (PXR) and Constitutive Androstane (CAR) receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus> **\]**) are members of the NR1I family of nuclear receptors, which form heterodimers with members of the retinoid X receptor family. PXR and CAR are activated by a range of exogenous compounds, with no established endogenous physiological agonists, although high concentrations of bile acids and bile pigments activate PXR and CAR \[<http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=605><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=606><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=607>Systematic nomenclatureNR1I1NR1I2NR1I3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12679](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12679), <http://www.uniprot.org/uniprot/P11473>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7968](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7968), <http://www.uniprot.org/uniprot/O75469>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7969](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7969), <http://www.uniprot.org/uniprot/Q14994>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779> \[<http://www.ncbi.nlm.nih.gov/pubmed/7976510?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12089348?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013> \[<http://www.ncbi.nlm.nih.gov/pubmed/10628745?dopt=AbstractPlus>\]--Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2777> \[<http://www.ncbi.nlm.nih.gov/pubmed/1472092?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8573413?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2790><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2764> \[<http://www.ncbi.nlm.nih.gov/pubmed/10852961?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10974665?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2759> \[<http://www.ncbi.nlm.nih.gov/pubmed/10628745?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739> \[<http://www.ncbi.nlm.nih.gov/pubmed/9727070?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765> \[<http://www.ncbi.nlm.nih.gov/pubmed/9784494?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9727070?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2756> \[<http://www.ncbi.nlm.nih.gov/pubmed/10757780?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2758> \[<http://www.ncbi.nlm.nih.gov/pubmed/12611900?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2788> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17125259?dopt=AbstractPlus>\] -- Chicken, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2789> (pIC^50^ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12901907?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11094341?dopt=AbstractPlus>\]----Comments----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330> \[<http://www.ncbi.nlm.nih.gov/pubmed/10748001?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2755> \[<http://www.ncbi.nlm.nih.gov/pubmed/23665929?dopt=AbstractPlus>\] although acting at other sites, function as antagonists of the constitutive androstane receptor.

Further reading on 1I. Vitamin D receptor‐like receptors {#bph14750-sec-0030}
--------------------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Long MD *et al*. (2015) Vitamin D receptor and RXR in the post‐genomic era. *J. Cell. Physiol*. **230**: 758‐66 <https://www.ncbi.nlm.nih.gov/pubmed/25335912?dopt=AbstractPlus>

Moore DD *et al*. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. *Pharmacol. Rev*. **58**: 742‐59 <https://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=91> {#bph14750-sec-0031}
==========================================================================

Overview {#bph14750-sec-0032}
--------

The nomenclature of hepatocyte nuclear factor‐4 receptors is agreed by the **[NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**. While linoleic acid has been identified as the endogenous ligand for HNF4α its function remains ambiguous \[<http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus>\]. HNF4γ has yet to be paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=608><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=609>Systematic nomenclatureNR2A1NR2A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5024](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5024), <http://www.uniprot.org/uniprot/P41235>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5026](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5026), <http://www.uniprot.org/uniprot/Q14541>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052> \[<http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus>\]--Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6695> \[<http://www.ncbi.nlm.nih.gov/pubmed/22840769?dopt=AbstractPlus>\]--CommentsHNF4α has constitutive transactivation activity \[<http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus>\] and binds DNA as a homodimer \[<http://www.ncbi.nlm.nih.gov/pubmed/7651430?dopt=AbstractPlus>\].--

Further reading on 2A. Hepatocyte nuclear factor‐4 receptors {#bph14750-sec-0033}
------------------------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Garattini E *et al*. (2016) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic targets in breast‐cancer. *Oncotarget* **7**: 42661‐42682 <https://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Lu H. (2016) Crosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. *Acta Pharm Sin B* **6**: 393‐408 <https://www.ncbi.nlm.nih.gov/pubmed/27709008?dopt=AbstractPlus>

Walesky C *et al*. (2015) Role of hepatocyte nuclear factor 4α (HNF4α) in cell proliferation and cancer. *Gene Expr*. **16**: 101‐8 <https://www.ncbi.nlm.nih.gov/pubmed/25700366?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=92> {#bph14750-sec-0034}
==========================================================================

Overview {#bph14750-sec-0035}
--------

Retinoid X receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132853?dopt=AbstractPlus> **\]**) are NR2B family members activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645> and the RXR‐selective agonists <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2808>, sometimes referred to as rexinoids. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2816> \[<http://www.ncbi.nlm.nih.gov/pubmed/17947383?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8079> \[<http://www.ncbi.nlm.nih.gov/pubmed/10748721?dopt=AbstractPlus>\] have been described as a pan‐RXR antagonists. These receptors form RXR‐RAR heterodimers and RXR‐RXR homodimers \[<http://www.ncbi.nlm.nih.gov/pubmed/8801176?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8521508?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=610><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=611><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=612>Systematic nomenclatureNR2B1NR2B2NR2B3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10477](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10477), <http://www.uniprot.org/uniprot/P19793>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10478](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10478), <http://www.uniprot.org/uniprot/P28702>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10479](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10479), <http://www.uniprot.org/uniprot/P48443>Sub/family‐selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807> \[<http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807> \[<http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807> \[<http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus>\]Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2810> \[<http://www.ncbi.nlm.nih.gov/pubmed/11805839?dopt=AbstractPlus>\]----

Further reading on 2B. Retinoid X receptors {#bph14750-sec-0036}
-------------------------------------------

Germain P *et al*. (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. *Pharmacol. Rev*. **58**: 760‐72 <https://www.ncbi.nlm.nih.gov/pubmed/17132853?dopt=AbstractPlus>

Long MD *et al*. (2015) Vitamin D receptor and RXR in the post‐genomic era. *J. Cell. Physiol*. **230**: 758‐66 <https://www.ncbi.nlm.nih.gov/pubmed/25335912?dopt=AbstractPlus>

Menéndez‐Gutiérrez MP *et al*. (2017) The multi‐faceted role of retinoid X receptor in bone remodeling. *Cell. Mol. Life Sci*. **74**: 2135‐2149 <https://www.ncbi.nlm.nih.gov/pubmed/28105491?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=93> {#bph14750-sec-0037}
==========================================================================

Overview {#bph14750-sec-0038}
--------

Testicular receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand, although testicular receptor 4 has been reported to respond to retinoids.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=613><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=614>Systematic nomenclatureNR2C1NR2C2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7971](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7971), <http://www.uniprot.org/uniprot/P13056>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7972](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7972), <http://www.uniprot.org/uniprot/P49116>Endogenous agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053> \[<http://www.ncbi.nlm.nih.gov/pubmed/21068381?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644> \[<http://www.ncbi.nlm.nih.gov/pubmed/21068381?dopt=AbstractPlus>\]CommentsForms a heterodimer with TR4; gene disruption appears without effect on testicular development or function \[<http://www.ncbi.nlm.nih.gov/pubmed/12052874?dopt=AbstractPlus>\].Forms a heterodimer with TR2.

Further reading on 2C. Testicular receptors {#bph14750-sec-0039}
-------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Safe S *et al*. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. *Mol. Endocrinol*. **28**: 157‐72 <https://www.ncbi.nlm.nih.gov/pubmed/24295738?dopt=AbstractPlus>

Wu D *et al*. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. *Biochim. Biophys. Acta* **1866**: 23‐36 <https://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=94> {#bph14750-sec-0040}
==========================================================================

Overview {#bph14750-sec-0041}
--------

Tailless‐like receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=615><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=616>Systematic nomenclatureNR2E1NR2E3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7973](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7973), <http://www.uniprot.org/uniprot/Q9Y466>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7974](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7974), <http://www.uniprot.org/uniprot/Q9Y5X4>CommentsGene disruption is associated with abnormal brain development \[<http://www.ncbi.nlm.nih.gov/pubmed/12902391?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9394001?dopt=AbstractPlus>\].--

Further reading on 2E. Tailless‐like receptors {#bph14750-sec-0042}
----------------------------------------------

Benod C *et al*. (2016) TLX: An elusive receptor. *J. Steroid Biochem. Mol. Biol*. **157**: 41‐7 <https://www.ncbi.nlm.nih.gov/pubmed/26554934?dopt=AbstractPlus>

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

O'Leary JD *et al*. (2018) Regulation of behaviour by the nuclear receptor TLX. *Genes Brain Behav*. **17**: e12357 <https://www.ncbi.nlm.nih.gov/pubmed/27790850?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=95> {#bph14750-sec-0043}
==========================================================================

Overview {#bph14750-sec-0044}
--------

COUP‐TF‐like receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=617><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=618><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=619>Systematic nomenclatureNR2F1NR2F2NR2F6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7975](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7975), <http://www.uniprot.org/uniprot/P10589>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7976](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7976), <http://www.uniprot.org/uniprot/P24468>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7977](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7977), <http://www.uniprot.org/uniprot/P10588>CommentsGene disruption is perinatally lethal \[<http://www.ncbi.nlm.nih.gov/pubmed/9271116?dopt=AbstractPlus>\].Gene disruption is embryonically lethal \[<http://www.ncbi.nlm.nih.gov/pubmed/10215630?dopt=AbstractPlus>\].Gene disruption impairs CNS development \[<http://www.ncbi.nlm.nih.gov/pubmed/15741322?dopt=AbstractPlus>\].

Further reading on 2F. COUP‐TF‐like receptors {#bph14750-sec-0045}
---------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Wu D *et al*. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. *Biochim. Biophys. Acta* **1866**: 23‐36 <https://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus>

Wu SP *etal*. (2016) Choose your destiny: Make a cell fate decision with COUP‐TFII. *J. Steroid Biochem. Mol. Biol*. **157**: 7‐12 <https://www.ncbi.nlm.nih.gov/pubmed/26658017?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=97> {#bph14750-sec-0046}
==========================================================================

Overview {#bph14750-sec-0047}
--------

Estrogen‐related receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=623><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=624>Systematic nomenclatureNR3B1NR3B2NR3B3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3471](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3471), <http://www.uniprot.org/uniprot/P11474>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3473](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3473), <http://www.uniprot.org/uniprot/O95718>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3474](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3474), <http://www.uniprot.org/uniprot/P62508>CommentsActivated by some dietary flavonoids \[<http://www.ncbi.nlm.nih.gov/pubmed/14638870?dopt=AbstractPlus>\]; activated by the synthetic agonist <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2835> \[<http://www.ncbi.nlm.nih.gov/pubmed/15857113?dopt=AbstractPlus>\] and blocked by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2832> \[<http://www.ncbi.nlm.nih.gov/pubmed/15184675?dopt=AbstractPlus>\].Maybe activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713377?dopt=AbstractPlus>\].Maybe activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713377?dopt=AbstractPlus>\].

Further reading on 3B. Estrogen‐related receptors {#bph14750-sec-0048}
-------------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Divekar SD *et al*. (2016) Estrogen‐related receptor β (ERRβ) ‐ renaissance receptor or receptor renaissance? *Nucl Recept Signal* **14**: e002 <https://www.ncbi.nlm.nih.gov/pubmed/27507929?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Tam IS *et al*. (2016) There and back again: The journey of the estrogen‐related receptors in the cancer realm. *J. Steroid Biochem. Mol. Biol*. **157**: 13‐9 <https://www.ncbi.nlm.nih.gov/pubmed/26151739?dopt=AbstractPlus>

Wu D *et al*. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. *Biochim. Biophys. Acta* **1866**: 23‐36 <https://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=99> {#bph14750-sec-0049}
==========================================================================

Overview {#bph14750-sec-0050}
--------

Nerve growth factor IB‐like receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=629><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=630><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=631>Systematic nomenclatureNR4A1NR4A2NR4A3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7980](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7980), <http://www.uniprot.org/uniprot/P22736>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7981](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7981), <http://www.uniprot.org/uniprot/P43354>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7982](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7982), <http://www.uniprot.org/uniprot/Q92570>CommentsAn endogenous agonist, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5424>, has been described \[<http://www.ncbi.nlm.nih.gov/pubmed/18690216?dopt=AbstractPlus>\], although structural analysis and molecular modelling has not identified a ligand binding site \[<http://www.ncbi.nlm.nih.gov/pubmed/12809604?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15716272?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12774125?dopt=AbstractPlus>\].----

Further reading on 4A. Nerve growth factor IB‐like receptors {#bph14750-sec-0051}
------------------------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Germain P*etal*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Ranhotra HS. (2015) The NR4A orphan nuclear receptors: mediators in metabolism and diseases. *J. Recept. Signal Transduct. Res*. **35**: 184‐8 <https://www.ncbi.nlm.nih.gov/pubmed/25089663?dopt=AbstractPlus>

Rodríguez‐Calvo R *et al*. (2017) The NR4A subfamily of nuclear receptors: potential new therapeutic targets for the treatment of inflammatory diseases. *Expert Opin. Ther. Targets* **21**: 291‐304 <https://www.ncbi.nlm.nih.gov/pubmed/28055275?dopt=AbstractPlus>

Safe S *et al*. (2016) Nuclear receptor 4A (NR4A) family ‐ orphans no more. *J. Steroid Biochem. Mol. Biol*. **157**: 48‐60 <https://www.ncbi.nlm.nih.gov/pubmed/25917081?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=100> {#bph14750-sec-0052}
===========================================================================

Overview {#bph14750-sec-0053}
--------

Fushi tarazu F1‐like receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=632><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=633>Systematic nomenclatureNR5A1NR5A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7983](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7983), <http://www.uniprot.org/uniprot/Q13285>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7984](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7984), <http://www.uniprot.org/uniprot/O00482>CommentsReported to be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5422> \[<http://www.ncbi.nlm.nih.gov/pubmed/18055761?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5423> \[<http://www.ncbi.nlm.nih.gov/pubmed/18334597?dopt=AbstractPlus>\].--

Further reading on 5A. Fushi tarazu F1‐like receptors {#bph14750-sec-0054}
-----------------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Garattini E *et al*. (2016) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic targets in breast‐cancer. *Oncotarget* **7**: 42661‐42682 <https://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Zhi X *et al*. (2016) Structures and regulation of non‐X orphan nuclear receptors: A retinoid hypothesis. *J. Steroid Biochem. Mol. Biol*. **157**: 27‐40 <https://www.ncbi.nlm.nih.gov/pubmed/26159912?dopt=AbstractPlus>

Zimmer V *et al*. (2015) Nuclear receptor variants in liver disease. *Dig Dis* **33**: 415‐9 <https://www.ncbi.nlm.nih.gov/pubmed/26045277?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=101> {#bph14750-sec-0055}
===========================================================================

Overview {#bph14750-sec-0056}
--------

Germ cell nuclear factor receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=634>Systematic nomenclatureNR6A1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7985](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7985), <http://www.uniprot.org/uniprot/Q15406>

Further reading on 6A. Germ cell nuclear factor receptors {#bph14750-sec-0057}
---------------------------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Garattini E *et al*. (2016) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic in breast‐cancer. *Oncotarget* **7**: 42661‐42682 <https://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Safe S *et al*. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug *Mol. Endocrinol*. **28**: 157‐72 <https://www.ncbi.nlm.nih.gov/pubmed/24295738?dopt=AbstractPlus>

Zhi X *et al*. (2016) Structures and regulation of non‐X orphan nuclear receptors: A retinoid hypothesis. *J. Steroid Biochem. Mol. Biol*. **157**: 27‐40 <https://www.ncbi.nlm.nih.gov/pubmed/26159912?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=102> {#bph14750-sec-0058}
===========================================================================

Overview {#bph14750-sec-0059}
--------

Dax‐like receptors (**nomenclature as agreed by the** [NC‐IUPHAR]{.ul} **Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus> **\]**) have yet to be officially paired with an endogenous ligand.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=635><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=636>Systematic nomenclatureNR0B1NR0B2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7960](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7960), <http://www.uniprot.org/uniprot/P51843>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7961](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7961), <http://www.uniprot.org/uniprot/Q15466>

Further reading on 0B. DAX‐like receptors {#bph14750-sec-0060}
-----------------------------------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev*. **58**: 798‐836 <https://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus>

Garattini E *et al*. (2016) Lipid‐sensors, enigmatic‐orphan and orphan nuclear receptors as therapeutic targets in breast‐cancer. *Oncotarget* **7**: 42661‐42682 <https://www.ncbi.nlm.nih.gov/pubmed/26894976?dopt=AbstractPlus>

Germain P *et al*. (2006) Overview of nomenclature of nuclear receptors. *Pharmacol. Rev*. **58**: 685‐704 <https://www.ncbi.nlm.nih.gov/pubmed/17132848?dopt=AbstractPlus>

Safe S *et al*. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. *Mol. Endocrinol*. **28**: 157‐72 <https://www.ncbi.nlm.nih.gov/pubmed/24295738?dopt=AbstractPlus>

Wu D *et al*. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. *Biochim. Biophys. Acta* **1866**: 23‐36 <https://www.ncbi.nlm.nih.gov/pubmed/27264242?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=107> {#bph14750-sec-0061}
===========================================================================

Overview {#bph14750-sec-0062}
--------

Steroid hormone receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132854?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17132855?dopt=AbstractPlus> **\]**) are nuclear hormone receptors of the NR3 class, with endogenous agonists that may be divided into 3‐hydroxysteroids (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013>) and 3‐ketosteroids (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856> \[DHT\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858>). These receptors exist as dimers coupled with chaperone molecules (such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5365> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5258](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5258), <http://www.uniprot.org/uniprot/P08238>) and immunophilin FKBP52:[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3720](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3720), <http://www.uniprot.org/uniprot/Q02790>), which are shed on binding the steroid hormone. Although rapid signalling phenomena are observed \[<http://www.ncbi.nlm.nih.gov/pubmed/18784332?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19389460?dopt=AbstractPlus>\], the principal signalling cascade appears to involve binding of the activated receptors to nuclear hormone response elements of the genome, with a 15‐nucleotide consensus sequence AGAACAnnnTGTTCT (*i.e*. an inverted palindrome) as homo‐ or heterodimers. They also affect transcription by protein‐protein interactions with other transcription factors, such as activator protein 1 (AP‐1) and nuclear factor *~κ~*B (NF‐*~κ~*B). Splice variants of each of these receptors can form functional or non‐functional monomers that can dimerize to form functional or non‐functional receptors. For example, alternative splicing of PR mRNA produces A and B monomers that combine to produce functional AA, AB and BB receptors with distinct characteristics \[<http://www.ncbi.nlm.nih.gov/pubmed/8264658?dopt=AbstractPlus>\].

A 7TM receptor responsive to estrogen ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4485](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4485), <http://www.uniprot.org/uniprot/Q99527>, also known as GPR30, see \[<http://www.ncbi.nlm.nih.gov/pubmed/18271749?dopt=AbstractPlus>\]) has been described. Human orthologues of 7TM 'membrane progestin receptors' ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23146](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23146), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15708](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15708) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29645](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29645)), initially discovered in fish \[<http://www.ncbi.nlm.nih.gov/pubmed/12601167?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12574519?dopt=AbstractPlus>\], appear to localize to intracellular membranes and respond to 'non‐genomic' progesterone analogues independently of G proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/18603275?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=96> {#bph14750-sec-0063}
==========================================================================

Overview {#bph14750-sec-0064}
--------

Estrogen receptor (ER) activity regulates diverse physiological processes *via* transcriptional modulation of target genes. The selection of target genes and the magnitude of the response, be it induction or repression, are determined by many factors, including the effect of the hormone ligand and DNA binding on ER structural conformation, and the local cellular regulatory environment. The cellular environment defines the specific complement of DNA enhancer and promoter elements present and the availability of coregulators to form functional transcription complexes. Together, these determinants control the resulting biological response.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621>Systematic nomenclatureNR3A1NR3A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3467](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3467), <http://www.uniprot.org/uniprot/P03372>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3468](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3468), <http://www.uniprot.org/uniprot/Q92731>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2821> \[<http://www.ncbi.nlm.nih.gov/pubmed/9048584?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818> \[<http://www.ncbi.nlm.nih.gov/pubmed/9048584?dopt=AbstractPlus>\]--Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2819> \[<http://www.ncbi.nlm.nih.gov/pubmed/11014206?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11150164?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7071> \[<http://www.ncbi.nlm.nih.gov/pubmed/16722623?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4052> \[<http://www.ncbi.nlm.nih.gov/pubmed/15456246?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2825> \[<http://www.ncbi.nlm.nih.gov/pubmed/11708925?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11150164?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6700> \[<http://www.ncbi.nlm.nih.gov/pubmed/18097065?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15456246?dopt=AbstractPlus>\]Sub/family‐selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11356100?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/11356100?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4159> (p*K* ~i~ 8.9) \[2\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3459> (p*K* ~i~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11861516?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2822> (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/10395487?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9927308?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3461> (p*K* ~i~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17228884?dopt=AbstractPlus>\]

Comments {#bph14750-sec-0065}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2822> exhibits partial agonist activity at ERα \[<http://www.ncbi.nlm.nih.gov/pubmed/10395487?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9927308?dopt=AbstractPlus>\]. Estrogen receptors may be blocked non‐selectively by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820> and labelled by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1012> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5384>. Many agents thought initially to be antagonists at estrogen receptors appear to have tissue‐specific efficacy (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016> is an antagonist at estrogen receptors in the breast, but is an agonist at estrogen receptors in the uterus), hence the descriptor SERM (selective estrogen receptor modulator) or SnuRM (selective nuclear receptor modulator). <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5430> has been suggested to be an ERα‐selective estrogen receptor modulator \[<http://www.ncbi.nlm.nih.gov/pubmed/17115070?dopt=AbstractPlus>\].

Further reading on 3A. Estrogen receptors {#bph14750-sec-0066}
-----------------------------------------

Coons LA *et al*. (2017) DNA Sequence Constraints Define Functionally Active Steroid Nuclear Receptor Binding Sites in Chromatin. *Endocrinology* **158**: 3212‐3234 <https://www.ncbi.nlm.nih.gov/pubmed/28977594?dopt=AbstractPlus>

Dahlman‐Wright K *et al*. (2006) International Union of Pharmacology. LXIV. Estrogen receptors. *Pharmacol. Rev*. **58**: 773‐81 <https://www.ncbi.nlm.nih.gov/pubmed/17132854?dopt=AbstractPlus>

Gonzalez‐Sanchez E *et al*. (2015) Nuclear receptors in acute and chronic cholestasis. *Dig Dis* **33**: 357‐66 <https://www.ncbi.nlm.nih.gov/pubmed/26045270?dopt=AbstractPlus>

Hewitt SC *et al*. (2016) What's new in estrogen receptor action in the female reproductive tract. *J. Mol. Endocrinol*. **56**: R55‐71 <https://www.ncbi.nlm.nih.gov/pubmed/26826253?dopt=AbstractPlus>

Jameera Begam A *et al*. (2017) Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. *Bioorg. Chem*. **71**: 257‐274 <https://www.ncbi.nlm.nih.gov/pubmed/28274582?dopt=AbstractPlus>

Warner M *et al*. (2017) Estrogen Receptor β as a Pharmaceutical Target. *Trends Pharmacol. Sci*. **38**: 92‐99 <https://www.ncbi.nlm.nih.gov/pubmed/27979317?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=98> {#bph14750-sec-0067}
==========================================================================

Overview {#bph14750-sec-0068}
--------

Steroid hormone receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Nuclear Hormone Receptors \[** <http://www.ncbi.nlm.nih.gov/pubmed/17132854?dopt=AbstractPlus>, <https://www.ncbi.nlm.nih.gov/pubmed/17132855?dopt=AbstractPlus> **\]**) are nuclear hormone receptors of the NR3 class, with endogenous agonists that may be divided into 3‐hydroxysteroids (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013>) and 3‐ketosteroids (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856> \[DHT\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=625><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627>Systematic nomenclatureNR3C4NR3C1NR3C2NR3C3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:644](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:644), <http://www.uniprot.org/uniprot/P10275>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7978](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7978), <http://www.uniprot.org/uniprot/P04150>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7979](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7979), <http://www.uniprot.org/uniprot/P08235>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8910](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8910), <http://www.uniprot.org/uniprot/P06401>Rank order of potency<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856> *\>* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450> \[<http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377> \[<http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856> \[<http://www.ncbi.nlm.nih.gov/pubmed/2911578?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872> \[<http://www.ncbi.nlm.nih.gov/pubmed/10611474?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377> \[<http://www.ncbi.nlm.nih.gov/pubmed/9667968?dopt=AbstractPlus>\]Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7100> \[<http://www.ncbi.nlm.nih.gov/pubmed/17574413?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2859> \[<http://www.ncbi.nlm.nih.gov/pubmed/10852459?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2861> \[<http://www.ncbi.nlm.nih.gov/pubmed/17439112?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2857> \[<http://www.ncbi.nlm.nih.gov/pubmed/10076535?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6947><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7080> \[<http://www.ncbi.nlm.nih.gov/pubmed/10633034?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7076> \[2\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7059> \[2\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7088> \[2\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7061> \[2\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7434> \[<http://www.ncbi.nlm.nih.gov/pubmed/21880489?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2879> (Affinity at human PR‐A) \[<http://www.ncbi.nlm.nih.gov/pubmed/9464360?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3453>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2881> \[<http://www.ncbi.nlm.nih.gov/pubmed/6645495?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14670641?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2863> (p*K* ~i~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16420057?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6698> (pIC~50~ 7.1--7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18921992?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6812> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19359544?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2864> (pIC~50~ 7.1--7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9111629?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2862> (pEC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/10076535?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/15828836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6943> (Displacement of ^3^\[H\] testosterone from wild‐type androgen receptors) (p*K* ~i~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/18571420?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/12781198?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8678> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22791416?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2876> (p*K* ~i~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18038968?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882> (pIC~50~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/12781198?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3451>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7460> (pIC~50~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18243712?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2805> (Mixed) (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/12781197?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882> (p*K* ~i~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8627601?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448>Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3455> (Selective Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3457> (Selective Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3456> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3447> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3452> (Selective Agonist) \[<http://www.ncbi.nlm.nih.gov/pubmed/16188378?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/6320679?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3454> (Selective Agonist)

Comments {#bph14750-sec-0069}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3447> also binds to MR*in vitro*. PR antagonists have been suggested to subdivide into Type I (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882>) and Type II (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448>) groups. These groups appear to promote binding of PR to DNA with different efficacies and evoke distinct conformational changes in the receptor, leading to a transcription‐neutral complex \[<http://www.ncbi.nlm.nih.gov/pubmed/9528977?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9849965?dopt=AbstractPlus>\]. Mutations in AR underlie testicular feminization and androgen insensitivity syndromes, spinal and bulbar muscular atrophy (Kennedy's disease).

Further reading on 3C. 3‐Ketosteroid receptors {#bph14750-sec-0070}
----------------------------------------------
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